Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bristol Myers Squibb : Sets 2020 Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 07:40am EDT

By Dave Sebastian

Bristol-Myers Squibb Co. (BMY) on Thursday set its financial outlook for 2020 as it reported fourth-quarter loss and higher sales.

The pharmaceutical company expects 2020 revenue of $40.5 billion to $42.5 billion both on a reported and adjusted basis.

It sees earnings of 75 cents a share to 95 cents a share, or $6 a share to $6.20 a share on an adjusted basis.

The company said its guidance for 2020 and 2021 includes the effect of the Celgene acquisition and the Otezla divestiture.

Shares rose 1.1% in premarket trading.

Write to Dave Sebastian at dave.sebastian@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.60% 60.65 Delayed Quote.-5.51%
CELGENE 0.10% 108.24 Delayed Quote.68.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BRISTOL-MYERS SQUIBB COMPA
06/02BRISTOL MYERS SQUIBB : Compugen Announces FDA Clearance of IND Application for P..
AQ
06/02BRISTOL MYERS SQUIBB : Myers Phase 3 Zeposia Study in Ulcerative Colitis Meets K..
DJ
06/02BRISTOL MYERS SQUIBB : Announces Positive Topline Results from Pivotal Phase 3 T..
BU
06/01BRISTOL MYERS SQUIBB : Announces Commercial Launch and Availability of ZEPOSIA® ..
BU
05/29BRISTOL MYERS SQUIBB : to Hold Virtual Three-Part Investor Series
BU
05/28BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia for the..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/27BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
AQ
05/27BRISTOL MYERS SQUIBB : Gets European Union Approval for MS Drug Zeposia
DJ
05/27BRISTOL MYERS SQUIBB : Receives European Commission Approval for Zeposia (ozanim..
BU
More news
Financials (USD)
Sales 2020 41 932 M - -
Net income 2020 1 114 M - -
Net Debt 2020 27 322 M - -
P/E ratio 2020 116x
Yield 2020 2,95%
Capitalization 137 B 137 B -
EV / Sales 2019
EV / Sales 2020 3,92x
Nbr of Employees 30 000
Free-Float 77,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 72,00 $
Last Close Price 60,65 $
Spread / Highest target 36,9%
Spread / Average Target 18,7%
Spread / Lowest Target 2,23%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Senior Vice President
Vicki L. Sato Lead Independent Director
Gerald L. Storch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-5.51%137 232
JOHNSON & JOHNSON1.63%387 786
ROCHE HOLDING AG5.96%295 188
MERCK & CO., INC.-11.12%200 817
PFIZER, INC.-7.71%196 974
NOVARTIS AG-9.65%190 248